Why 'Wait and See' Is Sometimes the Right Call

Being told to wait when your knee hurts — and keeps hurting — can feel like being dismissed. It is worth understanding why a clinician might recommend that, because the reasoning is specific, not vague.

Articular cartilage has no direct blood supply, which means it cannot repair itself the way a muscle or ligament can. Once damaged, recovery is slow and often incomplete. That biology makes the decision to watch rather than operate a deliberate clinical calculation, not a shrug.

For lesions that are asymptomatic — picked up on a scan but causing no real functional problem — surgery introduces risk without clear benefit. Even for mild symptomatic defects, where the main complaint is a dull ache after activity with no locking, catching, or giving way, the evidence supports trying a structured conservative programme first: guided physiotherapy, anti-inflammatory medication where appropriate, and targeted joint injections where indicated. A minimum of three months is the established window.

There is also a practical upside to completing that programme: patients who finish it enter any subsequent procedure in better physical condition than those who skip straight to surgery.

Symptoms That Mean You Should Not Wait

Four symptoms change the calculation immediately — and if any of them sound familiar, a specialist review should be the next step, not more physiotherapy.

The knee locks. Not stiff — actually stuck. Unable to fully straighten or bend without forcing it or waiting it out. This points to a loose cartilage fragment caught inside the joint.

It catches or snaps. A sharp snag or audible pop mid-movement that differs from ordinary clicking suggests an unstable flap or fragment shifting where it should not be.

The knee gives way. It buckles unexpectedly — on stairs, on a kerb, or mid-stride. This is a mechanical failure, and it carries a genuine fall risk that worsens with continued loading.

Swelling that will not settle. Some reactive swelling with cartilage damage is expected. Swelling that is severe, progressive, or persistent after several days of rest signals active joint irritation that is unlikely to resolve on its own.

Each of these symptoms indicates an unstable or displaced fragment doing further damage with every step. The 'pothole' principle applies: a contained defect left under repeated impact sends cracks outward, turning a manageable lesion into a far harder problem to repair. For any of these presentations, early surgical assessment — not a three-month conservative trial — is the appropriate starting point.

The 3-Month Conservative Trial — and When It's Finished

Conservative care is not the same as doing nothing — and that distinction matters if you are currently in the middle of it.

A properly structured trial has defined contents. It typically includes supervised physiotherapy focused on load management and quadriceps strengthening; anti-inflammatory medication to reduce joint irritation; and, where appropriate, a steroid or hyaluronic acid injection to settle persistent swelling and improve pain-free movement. 'Rest and see how it goes' is not a conservative trial — it is informal waiting, and it is less likely to produce a clear answer at the end of it.

The standard minimum duration is three months. Formal clinical reassessment then takes place at 12–16 weeks. This is a decision gate, not another holding pattern. At that review, the clinician is asking a specific question: have symptoms improved enough to continue non-operative management, or has the programme run its course without adequate benefit?

The answer determines the next step. Persistent severe pain, swelling that has not settled, or worsening mechanical symptoms at the 12–16 week mark are indicators that conservative care has failed. Continuing beyond this point is not watchful — it is delay without clinical rationale. Surgical referral becomes the appropriate next step, and reaching it after a documented programme means the decision is well-supported rather than premature.

How Lesion Grade and Size Determine Which Treatment Fits

Scan results do not come labelled 'needs surgery' or 'does not' — but the two numbers your specialist will focus on, grade and defect size, do most of that work.

Grade: how deep the damage goes

Clinicians use the ICRS scale to describe depth. Think of your cartilage as a tiled surface over concrete:

• Grade 1–2 is surface crazing or softening to less than half the cartilage depth. The tile is scuffed or cracked but still covering the concrete. Conservative management — the structured programme described in the previous section — is typically the right starting point.
• Grade 3 reaches more than halfway through, approaching the calcified base layer. The crack is significant, and the response to conservative care is less predictable.
• Grade 4 is a hole through to the subchondral bone beneath — concrete exposed. At this depth, surgery is generally required once conservative care has been completed.

Size: why a fingernail-sized defect behaves differently from a postage-stamp one

A 2 cm² defect — roughly the area of a fingernail — may respond adequately to microfracture or a small osteochondral graft if conservative care has failed. Once a lesion reaches 3 cm² or more, the evidence shifts. The SUMMIT trial found that patients with defects of this size treated with MACI (a cell-based technique using the patient's own cartilage cells) had meaningfully better pain and function scores at both two and five years compared with microfracture alone. Applying a smaller-defect technique to a larger lesion is not a conservative choice — microfracture in isolation carries a real risk of subchondral bone changes and produces results comparable to simple debridement, making under-treatment its own form of delayed harm.

Comorbidities — including BMI, joint alignment, age, and whether any inflammatory arthritis is present — modify these thresholds in both directions. An MRI provides the map, but consultant-led assessment adds the clinical context needed to read it accurately.

What Treatment Actually Involves for Different Lesion Types

Crossing the threshold for intervention raises a more specific question: which procedure, for which lesion?

Smaller defects: microfracture and mosaicplasty

For focal lesions under roughly 2–4 cm² after a failed conservative trial, microfracture and mosaicplasty are the established first-line surgical options. Microfracture stimulates a healing response through the subchondral bone but produces fibrocartilage rather than native hyaline cartilage — less durable under repeated load. Mosaicplasty transfers small cartilage plugs from a low-load zone of the knee into the defect and can produce better tissue quality for the right lesion location.

Larger or higher-grade defects: cell-based and graft techniques

Once a lesion reaches 3 cm² or more, cell-based or graft techniques offer consistently better outcomes. ACI and MACI both use the patient's own cultured cartilage cells implanted on a scaffold. Five-year follow-up data from autologous minced cartilage repair — a single-stage cell technique — show pain falling from a median of 7/10 to 2/10, with 75% of patients reaching IKDC functional thresholds and a 3.5% revision rate. Osteochondral allograft is reserved for the most complex or largest defects.

Less-invasive pathways for suitable patients

For patients whose defect pattern and joint profile make them appropriate candidates, less-invasive options exist alongside these surgical routes. NanoACi is a surgeon-led, needle-delivered, one-stage procedure — developed by Professor Paul Lee, MSK Doctors' lead cartilage specialist — that removes arthroscopy from the delivery pathway for suitable patients, aiming to create a chondrogenic repair environment directly at the defect site. ChondroFiller, a collagen-scaffold injectable for focal chondral defects, provides a structural matrix to support tissue repair in appropriately selected cases. Suitability for either is determined through specialist assessment and imaging rather than patient preference alone.

Recovery commitment

Whichever technique is used, recovery follows a similar staged arc: six weeks of protected weight-bearing, three to six months of progressive strengthening, and 12–18 months before return to high-impact or pivoting sport. That timetable is itself a reason not to defer a clearly indicated procedure — patients who enter surgery already significantly deconditioned face a harder rehabilitation, and the window for optimal tissue repair narrows as surrounding structures deteriorate.

The Assessment That Answers the Question

Getting to a clear answer requires two things a GP letter alone cannot provide: imaging detailed enough to grade the lesion, and a specialist consultation that places that image in full clinical context.

MRI is the primary diagnostic tool — it shows defect depth, surface area, and whether the subchondral bone beneath is involved, all of which govern the treatment tier. AI-assisted analysis can improve the precision of lesion characterisation on standard sequences where it is available. Objective biomechanical assessment — gait analysis or clinical examination of joint alignment — adds what a static scan cannot: how load is actually distributed across the knee in motion, and whether alignment or mechanics are accelerating the defect.

The consultant review integrates these findings with symptom history, comorbidities, activity goals, and BMI. The same 3 cm² Grade 3 lesion may warrant a different pathway in a patient with normal alignment than in one with a varus knee. A proper assessment concludes with a named management recommendation — not an instruction to return in six months.

If you would like a consultant assessment without a GP referral, MSK Doctors accepts direct bookings at mskdoctors.com. Grade and size determine technique — but only a full specialist review can establish both with the precision that treatment decisions require.